Abstract:Background & aims: Long-term studies of the prognosis of NAFLD are scarce. Here, we investigated the risk of major adverse liver outcomes (MALO) in a large cohort of patients with NAFLD. Methods: We conducted a cohort study with data from Swedish university hospitals. Patients (n = 1,260) with NAFLD without cirrhosis were diagnosed through biopsy or radiology, and had fibrosis estimated through vibration-controlled transient elastography, biopsy, or FIB-4 score between 1974 and 2020 and followed up through 2020. Each patient was matched on age, sex, and municipality with up to 10 reference individuals from the general population (n = 12,529). MALO were ascertained from Swedish national registers. The rate of events was estimated by Cox regression. Results: MALO occurred in 111 (8.8%, incidence rate = 5.9/1,000 person-years) patients with NAFLD and 197 (1.6%, incidence rate = 1.0/1,000 person-years) reference individuals during a median follow up of 13 years. The rate of MALO was higher in patients with NAFLD (hazard ratio = 6.6; 95% CI = 5.2-8.5). The risk of MALO was highly associated with the stage of fibrosis at diagnosis. In the biopsy subcohort (72% of total sample), there was no difference in risk between patients with and without non-alcoholic steatohepatitis. The 20-year cumulative incidences of MALO were 2% for the reference population, 3% for patients with F0, and 35% for F3. Prognostic information from biopsy was comparable to FIB-4 (C-indices around 0.73 vs. 0.72 at 10 years). Conclusions: This study provides updated information on the natural history of NAFLD, showing a high rate of progression to cirrhosis in F3 and a similar prognostic capacity of non-invasive tests to liver biopsy. Impact and implications: Several implications for clinical care and future research may be noted based on these results. First, the risk estimates for cirrhosis development are important when communicating risk to patients and deciding on clinical monitoring and treatment. Estimates can also be used in updated health-economic evaluations, and for regulatory agencies. Second, our results again highlight the low predictive information obtained from ascertaining NASHstatus by histology and call for more objective means by which to define NASH. Such methods may include artificial intelligence-supported digital pathology. We highlight that NASH is most likely the causal factor for fibrosis progression in NAFLD, but the subjective definition makes the prognostic value of a histological NASH diagnosis of limited value. Third, the finding that prognostic information from biopsy and the very simple Fibrosis-4 score were comparable is important as it may lead to fewer biopsies and further move the field towards non-invasive means by which to define fibrosis and, importantly, use non-invasive tests as outcomes in clinical trials. However, all modalities had modest discriminatory capacity and new risk stratification systems are needed in NAFLD. Repeated measures of non-invasive scores may be a potential solution.

Risk of major adverse liver outcomes among first‐degree relatives of individuals with MASLD

Risk of Major Adverse Cardiovascular Outcomes in Families With MASLD: A Population-Based Multigenerational Cohort Study

Misclassified ALD is common in presumed MASLD and highly increases risk for future cirrhosis

Prevalence and determinants of liver disease in relatives of Italian patients with advanced MASLD

Socioeconomic factors associated with the presence of and outcomes in metabolic dysfunction-associated steatotic liver disease

Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis

Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake

Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study

PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic-associated steatotic liver disease

Association between MASLD and increased risk of serious bacterial infections requiring hospital admission: A meta-analysis

Differential effects of genetic polymorphism on comorbid disease in metabolic dysfunction-associated steatotic liver disease

Impact of MASLD and MetALD on clinical outcomes: A meta‐analysis of preliminary evidence

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD

Identifying and Linking Patients At Risk for MASLD with Advanced Fibrosis to Care in Primary Care

From NAFLD to MASLD: when Metabolic Comorbidity Matters.

Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study

Birth Weight, Gestational Age, and Risk of Pediatric-Onset MASLD

Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study

Long-term Outcomes and Risk Modifiers of MASLD Between Lean and Non-Lean Populations

Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD

MAFLD predicts cardiovascular disease risk better than MASLD